GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Cyclically Adjusted Price-to-FCF

Zynex (ZYXI) Cyclically Adjusted Price-to-FCF : 57.42 (As of May. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Zynex Cyclically Adjusted Price-to-FCF?

As of today (2024-05-16), Zynex's current share price is $10.91. Zynex's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.19. Zynex's Cyclically Adjusted Price-to-FCF for today is 57.42.

The historical rank and industry rank for Zynex's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ZYXI' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 43.18   Med: 140.73   Max: 371.17
Current: 57.7

During the past years, Zynex's highest Cyclically Adjusted Price-to-FCF was 371.17. The lowest was 43.18. And the median was 140.73.

ZYXI's Cyclically Adjusted Price-to-FCF is ranked worse than
78.79% of 33 companies
in the Medical Distribution industry
Industry Median: 29.06 vs ZYXI: 57.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Zynex's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.058. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.19 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zynex Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Zynex's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Cyclically Adjusted Price-to-FCF Chart

Zynex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.56 205.36 105.84 104.36 57.39

Zynex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.05 64.43 45.99 57.39 64.83

Competitive Comparison of Zynex's Cyclically Adjusted Price-to-FCF

For the Medical Distribution subindustry, Zynex's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynex's Cyclically Adjusted Price-to-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zynex's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zynex's Cyclically Adjusted Price-to-FCF falls into.



Zynex Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Zynex's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=10.91/0.19
=57.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zynex's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zynex's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.058/131.7762*131.7762
=0.058

Current CPI (Mar. 2024) = 131.7762.

Zynex Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.021 100.560 0.028
201409 0.009 100.428 0.012
201412 -0.002 99.070 -0.003
201503 0.005 99.621 0.007
201506 -0.010 100.684 -0.013
201509 0.008 100.392 0.011
201512 0.008 99.792 0.011
201603 0.019 100.470 0.025
201606 0.003 101.688 0.004
201609 0.012 101.861 0.016
201612 0.017 101.863 0.022
201703 -0.001 102.862 -0.001
201706 0.051 103.349 0.065
201709 0.074 104.136 0.094
201712 0.095 104.011 0.120
201803 0.022 105.290 0.028
201806 0.057 106.317 0.071
201809 0.078 106.507 0.097
201812 0.066 105.998 0.082
201903 0.046 107.251 0.057
201906 0.014 108.070 0.017
201909 0.049 108.329 0.060
201912 0.055 108.420 0.067
202003 0.009 108.902 0.011
202006 0.061 108.767 0.074
202009 -0.022 109.815 -0.026
202012 -0.049 109.897 -0.059
202103 -0.146 111.754 -0.172
202106 0.025 114.631 0.029
202109 0.093 115.734 0.106
202112 0.187 117.630 0.209
202203 0.041 121.301 0.045
202206 -0.008 125.017 -0.008
202209 0.188 125.227 0.198
202212 0.125 125.222 0.132
202303 0.047 127.348 0.049
202306 0.014 128.729 0.014
202309 0.240 129.860 0.244
202312 0.165 129.419 0.168
202403 0.058 131.776 0.058

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zynex  (NAS:ZYXI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Zynex Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Zynex's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynex (ZYXI) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.
Executives
Daniel J Moorhead officer: Chief Financial Officer 9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok officer: See Remarks 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard director, 10 percent owner, officer: President, CEO and Chairman 10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery officer: See Remarks C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow director AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress director 3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc 10 percent owner 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea officer: Chief Operating Officer C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112